Cipla scored highest among pharma companies in CRISIL’s Sustainability Rating 2022 Kumar Jeetendra | May 25, 2022 Mumbai, India; May 25, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that is has been rated ‘STRONG’ in the Sustainability Yearbook 2022 released by CRISIL, a leading rating agency in India. Based on the fiscal 2021 data, CRISIL analysed 586 companies across 53 sectors for over …
Alembic Pharmaceuticals announces USFDA Final Approval for Arformoterol Tartrate Inhalation Solution, 15 mcg (base)/2 mL Unit-dose Vial Kumar Jeetendra | May 11, 2022 11 May 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution, 15 mcg (base)/2 mL Unit-dose Vial. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), …
Cipla Launches ‘RT Direct’ Multiplex real time PCR kit for Covid-19 RNA extraction free kit to deliver results in just 45 Min Kumar Jeetendra | May 10, 2022 Mumbai, India; May 10, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of ‘RT-Direct’ multiplex COVID-19 RT PCR Test kit in India, in partnership with Genes2Me Pvt. Ltd. With this, Cipla is expanding its diagnostics offering to bring more advanced and innovative products. Cipla will be responsible …
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Docosanol Cream, 10% (OTC) Kumar Jeetendra | May 4, 2022 4th May 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Docosanol Cream, 10% (OTC). The approved ANDA is therapeutically equivalent to the reference listed drug product …
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Clobetasol Propionate Foam, 0.05%. Kumar Jeetendra | April 28, 2022 25th April 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Foam, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product …
Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. Kumar Jeetendra | April 20, 2022 20th April 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ivabradine Tablets, 5 mg and 7.5 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Corlanor Tablets, …
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Lidocaine and Prilocaine Cream USP, 2.5%/2.5%. Kumar Jeetendra | April 12, 2022 12th April 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lidocaine and Prilocaine Cream USP, 2.5%/2.5%. The approved ANDA is therapeutically equivalent to the reference listed …
Alembic Pharmaceuticals announces USFDA Tentative Approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg. Kumar Jeetendra | April 7, 2022 7th April, 2022, Mumbai: Alembic Pharmaceuticals Limited today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) …
Inhalation Sciences signs IRS contract worth 491,000 SEK with returning nanotechnology client Kumar Jeetendra | April 1, 2022 A leading nanotechnology company has returned to carry out another research project with Inhalation Research Services (IRS), ISAB’s contract research organization. The previous project, worth 584,000 SEK, began in February 2022. The new project, worth 491,000 SEK, will test slightly different versions of the company’s porous inhalable nanoparticles. Further studies with the same client are …
Alembic pharmaceuticals acquires 100% stake in Aleor Dermaceuticals Kumar Jeetendra | March 29, 2022 Alembic Pharmaceuticals Limited (“Alembic” or “the Company”) has acquired the balance 40% stake in Aleor Dermaceuticals Limited (“Aleor”) from its JV Partner Orbicular Pharmaceutical Technologies Private Limited (“Orbicular”) to strengthen its skin-related manufacturing and marketing footprint. Aleor has product offerings across Cream, Gel, Ointment, Shampoo, Lotion, Solutions, Sprays, Foams, Microsponge and Nanoparticulate platform-based products. The …
Alembic Pharmaceuticals receives USFDA Tentative Approval for Macitentan Tablets, 10 mg. Kumar Jeetendra | March 14, 2022 14th March 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Macitentan Tablets, 10 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Opsumit Tablets, 10 mg, of …
Alembic Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Final Approval for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram. Kumar Jeetendra | March 8, 2022 8th March 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram. The approved ANDA is therapeutically equivalent to the reference …
